AIBIOS
AIBIOS has designed and developed a series of novel small molecules which modulate both the innate (macrophages) and adaptive immune system to treat therapeutic indications of Gastroenterology, Respiratory, and Neurological diseases.
AIBIOS
Industry:
Biotechnology
Founded:
2018-02-12
Address:
Irvine, California, United States
Country:
United States
Website Url:
http://www.aibios.com
Total Employee:
1+
Status:
Active
Contact:
949-812-8023
Email Addresses:
[email protected]
Total Funding:
850 M JPY
Technology used in webpage:
U.S. Server Location
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Dimension Therapeutics
Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases.
Georgiamune
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
iECURE
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
Integral Molecular
Integral Molecular is a research-driven biotechnology company creating innovative technologies and a pipeline of therapeutic antibodies
nference
nference is an Artificial Intelligence (AI)-powered venture creation engine
Peroxitech Therapeutics
Peroxitech Therapeutics operates as a biopharmaceutical company.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Current Employees Featured
Founder
Investors List
SBI Investment
SBI Investment investment in Seed Round - AIBIOS
Official Site Inspections
http://www.aibios.com Semrush global rank: 12.65 M Semrush visits lastest month: 89
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "AIBIOS"
AIBIOS Co. & Group
AIBIOS is a startup biotechnology company combines advanced science with expertise to bring new medicines to patients in need. Learn more.See details»
COMPANY | AIBIOS
AIBIOS is a startup biotechnology company combines advanced science with expertise to bring new medicines to patients in need. Learn more.See details»
AIBIOS - Crunchbase Company Profile & Funding
AIBIOS is a drug discovery and R&D biotech company with bioinformatics intelligence focusing on immune diseases.See details»
Aibios Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Aibios. Use the PitchBook Platform to explore the full profile.See details»
AIBIOS - Funding, Financials, Valuation & Investors
AIBIOS is a drug discovery and R&D biotech company with bioinformatics intelligence focusing on immune diseases.See details»
Aibios, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Aibios, Inc. with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Endocrinology and Metabolic Disease, Nervous System Diseases ...See details»
AIBIOS - Company Profile - Tracxn
Nov 27, 2024 AIBIOS - Developer of immunotherapeutics for immunology, cancer, and gastroenterology diseases. Raised funding from 1 investor.See details»
Aibios - Products, Competitors, Financials, Employees, …
Aibios is a biotechnology company focused on advancing the field of healthcare through scientific innovation. The company specializes in developing new medicines and healthcare …See details»
AIBIOS - Contacts, Employees, Board Members, Advisors & Alumni
AIBIOS is a drug discovery and R&D biotech company with bioinformatics intelligence focusing on immune diseases.See details»
SCIENCE | AIBIOS Co. & Group
AIBIOS concentrate our efforts on Immunology and Oncology area. We are developing a series of novel class of orally administered drugs with the potential to restore the balance of immune system. Our diverse and growing pipeline …See details»
Aibios Co., LTD. - SFRZ4 Details - GovTribe
UEI QL1CC3J9MA15 AIBIOS is a startup biotechnology company combines advanced science with expertise to bring new medicines to patients in need. Learn more. aibios.co.jp Primary …See details»
AIBIOS - Updates, News, Events, Signals & Triggers
Drug discovery and R&D biotech company with bioinformatics intelligence focusing on immune diseases.See details»
SUSTAINABILITY | AIBIOS Co. & Group
At AIBIOS we recognize the importance and urgency of this global initiative, we want to contribute to the achievement of the agenda by advancing the goals that align most closely with our …See details»
AIB-501 - Drug Targets, Indications, Patents - Synapse - Patsnap
AIB-501, Initially developed by Aibios, Inc., Now, its global highest R&D status is Discovery, Therapeutic Areas: Respiratory Diseases, Active Indication: Pulmonary ...See details»
CAREERS | AIBIOS Co. & Group
Our culture & values We are a startup biotech company that invents advanced science and technologies into therapies for people with serious diseases. At AIBIOS we know working …See details»
AIBIOS - Tech Stack, Apps, Patents & Trademarks - Crunchbase
AIBIOS is a drug discovery and R&D biotech company with bioinformatics intelligence focusing on immune diseases.See details»
AIB-302 - Drug Targets, Indications, Patents - Synapse
AIB-302, Initially developed by Aibios, Inc., Now, its global highest R&D status is Discontinued, Therapeutic Areas: Digestive System Disorders.See details»
BIOS 遇上大模型，系微推出“业界首款 AI 驱动固件辅助技 …
Jun 11, 2024 aiBIOS 技术将 AI 同系微的旗舰固件解决方案 InsydeH2O UEFI BIOS 相结合，既可分析电脑的硬件配置，也可借助大语言模型的术语知识库， 让用户快速理解 PC 专业术语。 …See details»
AIB-701 - Drug Targets, Indications, Patents - Synapse - Patsnap
AIB-701, Initially developed by Aibios, Inc., Now, its global highest R&D status is Discovery, Therapeutic Areas: Neoplasms, Active Indication: Neoplasms, Active Org ...See details»
NEWS | AIBIOS Co. & Group
The R&D team of AIBIOS has been focusing on immune-related research and finding new targets for novel immunotherapies. In this international conference, we will present the new progress …See details»